Chemoimmunotherapy of metastatic malignant melanoma The Salpétrière Hospital (SOMPS) experiences

This publication has 18 references indexed in Scilit:

• Recombinant interleukin-2 and other types of treatment of advanced malignant melanoma
  Current Opinion in Oncology, 1991
• Optimal two-stage designs for phase II clinical trials
  Controlled Clinical Trials, 1989
• Immunotherapy of cancer using interleukin 2: current status and future prospects
  Immunology Today, 1988
• The Development of New Immunotherapies for the Treatment of Cancer Using Interleukin-2
  Annals of Surgery, 1988
• A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
  New England Journal of Medicine, 1987
• Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer
  New England Journal of Medicine, 1987
• Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
  New England Journal of Medicine, 1985
• Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.
  The Journal of Experimental Medicine, 1984
• Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
  The Journal of Experimental Medicine, 1982
• Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.
  The Journal of Experimental Medicine, 1982